{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"No evidence of disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"1"}]}],"title":"Progressive disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Tumor responses evaluated using computed tomography and categorized according to RECIST version 1.0 at pre-treatment and 4 weeks after the last dose of study treatment. Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions \\[no evidence of disease\\]; Partial Response (PR): ≥ 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD): ≥ 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria.","groups":[{"description":"Subjects received MBV twice weekly by subcutaneous injection at a starting dose of 250 EU (dose level 1), with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed.","id":"OG000","title":"Cohort 1 (Tumor Response Analysis Set)"},{"description":"Subjects received MBV twice weekly by intralesional (preferred) or subcutaneous (if intralesional not possible) injection at the fixed dose (60,800 EU \\[dose level 6\\]) that was determined to be the pyrogenic dose level in Cohort 1.","id":"OG001","title":"Cohort 2 (Tumor Response Analysis Set)"}],"paramType":"NUMBER","populationDescription":"The Tumor Response Analysis Set comprises all subjects who had an end-of-study tumor assessment performed.","reportingStatus":"POSTED","timeFrame":"Up to 3 months","title":"Number of Participants With Best Overall Tumor Response","type":"SECONDARY","unitOfMeasure":"participants"}